Satellos Bioscience Inc. (MSCL.TO)

Satellos Bioscience Inc. (MSCL.TO) — VMCI valuation read

Satellos Bioscience Inc. sits at VMCI 38/100, with the Healthcare sector median at 50. That 12-point spread is the first thing to note on MSCL.TO: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on MSCL.TO are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on MSCL.TO: MSCL.TO trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 0.3x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

MSCL.TO fell 0.5% over the trailing 7 days, with a -6.5% read on a 30-day basis.